Search

Your search keyword '"Fersino S"' showing total 221 results
Start Over Author "Fersino S"
221 results on '"Fersino S"'

3. Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Author

Francolini, G, Borghesi, S, Fersino, S, Magli, A, Jereczek-Fossa, B, Cristinelli, L, Rizzo, M, Corvo, R, Pappagallo, G, Arcangeli, S, Magrini, S, D'Angelillo, R, Francolini G., Borghesi S., Fersino S., Magli A., Jereczek-Fossa B. A., Cristinelli L., Rizzo M., Corvo R., Pappagallo G. L., Arcangeli S., Magrini S. M., D'Angelillo R. M., Francolini, G, Borghesi, S, Fersino, S, Magli, A, Jereczek-Fossa, B, Cristinelli, L, Rizzo, M, Corvo, R, Pappagallo, G, Arcangeli, S, Magrini, S, D'Angelillo, R, Francolini G., Borghesi S., Fersino S., Magli A., Jereczek-Fossa B. A., Cristinelli L., Rizzo M., Corvo R., Pappagallo G. L., Arcangeli S., Magrini S. M., and D'Angelillo R. M.

Abstract

Aim: To compare trimodality therapy (TMT) versus radical cystectomy (RC) and develop GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) for treatment of muscle-invasive bladder cancer (MIBC). Material and Methods: Prospective and retrospective studies comparing TMT and RC for MIBC patients were included. Qualitative and quantitative evaluation of evidence was made. Results: Ten studies were included in the analysis. Pooled analysis showed salvage cystectomy and pathological complete response rates after TMT of 12 % and 72–77.5 %, respectively. Pooled rates of G3-G4 GU toxicity and serious toxicity rate were 18 vs 3% and 45 vs 29 % for patients undergoing TMT vs RC, respectively. The panel assessed a substantial equivalence in terms of OS and CSS at 5 years between TMT and RC. Conclusions: TMT could be suggested as an alternative treatment to RC in non-metastatic MIBC patients, deemed fit for surgery.

Published
2021

4. PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients

Author

Fersino, S, Borghesi, S, Jereczek-Fossa, B, Arcangeli, S, Mortellaro, G, Magrini, S, Alongi, F, Fersino S., Borghesi S., Jereczek-Fossa B. A., Arcangeli S., Mortellaro G., Magrini S. M., Alongi F., Fersino, S, Borghesi, S, Jereczek-Fossa, B, Arcangeli, S, Mortellaro, G, Magrini, S, Alongi, F, Fersino S., Borghesi S., Jereczek-Fossa B. A., Arcangeli S., Mortellaro G., Magrini S. M., and Alongi F.

Abstract

Aim: To investigate the actual attitude of Radiation Oncologists in the prescription of hormonal therapy in prostate cancer (PC) with or without Radiation Therapy (RT). Materials and methods: In 2019, a survey named Prescription of Radiation Oncologists ACtual Attitude including 18 items was sent to all Italian Radiation Oncologists of the Italian Association of Radiotherapy and Clinical Oncology. The first 4 items were about the Radiation Oncology Centers characteristics and years of practice of the respondents. The remaining 14 items concerned the setting in which hormone therapy was prescribed in PC patients (radical, postprostatectomy/oligometastatic state), the kind of drug, the choice modality (Multidisciplinary Group/autonomy decision) and other factors. Results: A total of 127 questionnaires were returned, mainly by Northern Italy Radiation Oncology Centres (44.9%), and by experienced Radiation Oncologists (78%), who declared to prescribe independently hormone therapy in 85.8% of cases. The Androgen deprivation therapy (ADT) prescription in castration naive PC was made independently by 56.7% of respondents and associated with radical RT, postoperative or salvage RT according to various risk factors. In castration-sensitive oligorecurrent PC, the majority (51.2%) administered ADT only if local ablative treatment was not feasible, while in metastatic castration resistant disease novel hormone therapy use was established in almost half of cases within multidisciplinary board. Radiation Oncologists could prescribe these drugs independently in 64% of cases. Conclusion: Our survey established the prescription attitude of ADT and new hormonal agents (abiraterone, enzalutamide, apalutamide) by Italian Radiation Oncologists and highlighted the importance of expertise in global PC management.

Published
2021

5. Cachexia induces head and neck changes in locally advanced oropharyngeal carcinoma during definitive cisplatin and image-guided volumetric-modulated arc radiation therapy

Author

Mazzola, R., Ricchetti, F., Florentino, A., Di Paola, G., Fersino, S., Levra, N. Giaj, Ruggieri, R., and Alongi, F.

Subjects
Cisplatin -- Health aspects, Radiotherapy -- Methods, Cachexia -- Care and treatment, Head and neck cancer -- Care and treatment, Food/cooking/nutrition, Health
Abstract

BACKGROUND/OBJECTIVES: Cancer cachexia is a syndrome characterized by weight loss (WL) and sarcopenia. Aim of the study was to assess the impact of cachexia on head and neck changes during definitive cisplatin and image-guided volumetric- modulated arc radiation therapy in a series of locally advanced oropharyngeal cancer. SUBJECTS/METHODS: Volume variations of sternocleidomastoid muscle (SCM) were considered as surrogate of muscle changes related to sarcopenia. Two head and neck diameters, encompassing the cranial limits of II and III nodal levels (defined as 'head diameter' and 'neck diameter', respectively), were measured. All parameters were defined retrospectively by means of on-board cone beam computed tomography images at 1-8th to 15-22th and at last fraction (fx) of radiotherapy (RT). Cachexia was defined as WL >5% during treatment. Analysis was conducted correlating the parameter changes with three WL ranges: < 5, 5-9 and > 10%. RESULTS: Thirty patients were evaluated. One hundred and fifty contoured SCMs and three hundred diameters were collected. Median WL was 6.5% (range, 0-16%). The most significant SCM shrinkage was recorded at 15th fx (mean 1.6 cc) related to WL 5-9% and WL > 10% (P 0.001). For 'head diameter', the peak reduction was recorded at the 15th fx (mean 8 mm), statistically correlated to WL > 10% (P 0.001). The peak reduction in 'neck diameter' was registered at the 22th fx (mean 6 mm), with a gradual reduction until the end of treatment for WL >5%. CONCLUSIONS: In a homogeneous cohort of patients, present study quantified the impact of cachexia on head and neck changes. Present data could provide adaptive RT implications for further investigations. European Journal of Clinical Nutrition (2016) 70, 738-742;doi:10.1038/ejcn.2016.61; published online 13 April 2016, INTRODUCTION In definitive chemo-radiotherapy (chemo-RT) for head and neck cancer (HNC), patient weight loss (WL) has shown detrimental effects on quality of life, performance status and compliance to treatment. (1) [...]

Published
2016
Full Text
View/download PDF

7. PO-1191 WBI and IORT for breast cancer: long-term results of a large mono-institution matched-pair analysis

Author

De Rose, F., primary, Di Brina, L., additional, Mussari, S., additional, Ravanelli, D., additional, Magri, E., additional, Proto, T., additional, Bandera, L., additional, Ferrazza, P., additional, Fersino, S., additional, Andolina, M., additional, Ziglio, F., additional, Delana, A., additional, Martignano, A., additional, Menegotti, L., additional, Bou Selman, S., additional, and Vanoni, V., additional

Published
2022
Full Text
View/download PDF

9. Guidelines on prostate carcinoma - AIRO, 2016

Author

Santoni, R, Arcangeli, S, Ingrosso, G, Antognoni, P, Mazzeo, E, D'Angelillo, R, Buglione, M, Borghesi, S, Petitti, T, Orecchia, R, Russi, E, Alitto, A, Alongi, F, Augurio, A, Bellavita, R, Bertoni, F, Bonetta, A, Bruni, A, Cagna, E, Cazzaniga, L, Corvo, R, D'Agostino, G, D'Amico, R, Detti, B, De Renzi, F, Fabrini, M, Fersino, S, Frascino, V, Gambarini, S, Genovesi, D, Grazioli, L, Guarneri, A, Jereczek-Fossa, B, Lancia, A, Livi, L, Magrini, S, Mantini, G, Mignogna, M, Mirri, M, Palumbo, I, Pergolizzi, S, Silvestro, G, Rubino, L, Tagliagambe, A, Tonoli, S, Valdagni, R, Vavassori, V, Vinciguerra, A, Santoni R., Arcangeli S., Ingrosso G., Antognoni P., Mazzeo E., D'angelillo R. M., Buglione M., Borghesi S., Petitti T., Orecchia R., Russi E., Alitto A., Alongi F., Augurio A., Bellavita R., Bertoni F., Bonetta A., Bruni A., Cagna E., Cazzaniga L. F., Corvo R., D'agostino G., D'amico R., Detti B., De Renzi F., Fabrini M. G., Fersino S., Frascino V., Gambarini S., Genovesi D., Grazioli L., Guarneri A., Jereczek-Fossa B. A., Lancia A., Livi L., Magrini S. M., Mantini G., Mignogna M., Mirri M. A., Palumbo I., Pergolizzi S., Silvestro G., Rubino L., Tagliagambe A., Tonoli S., Valdagni R., Vavassori V., Vinciguerra A., Santoni, R, Arcangeli, S, Ingrosso, G, Antognoni, P, Mazzeo, E, D'Angelillo, R, Buglione, M, Borghesi, S, Petitti, T, Orecchia, R, Russi, E, Alitto, A, Alongi, F, Augurio, A, Bellavita, R, Bertoni, F, Bonetta, A, Bruni, A, Cagna, E, Cazzaniga, L, Corvo, R, D'Agostino, G, D'Amico, R, Detti, B, De Renzi, F, Fabrini, M, Fersino, S, Frascino, V, Gambarini, S, Genovesi, D, Grazioli, L, Guarneri, A, Jereczek-Fossa, B, Lancia, A, Livi, L, Magrini, S, Mantini, G, Mignogna, M, Mirri, M, Palumbo, I, Pergolizzi, S, Silvestro, G, Rubino, L, Tagliagambe, A, Tonoli, S, Valdagni, R, Vavassori, V, Vinciguerra, A, Santoni R., Arcangeli S., Ingrosso G., Antognoni P., Mazzeo E., D'angelillo R. M., Buglione M., Borghesi S., Petitti T., Orecchia R., Russi E., Alitto A., Alongi F., Augurio A., Bellavita R., Bertoni F., Bonetta A., Bruni A., Cagna E., Cazzaniga L. F., Corvo R., D'agostino G., D'amico R., Detti B., De Renzi F., Fabrini M. G., Fersino S., Frascino V., Gambarini S., Genovesi D., Grazioli L., Guarneri A., Jereczek-Fossa B. A., Lancia A., Livi L., Magrini S. M., Mantini G., Mignogna M., Mirri M. A., Palumbo I., Pergolizzi S., Silvestro G., Rubino L., Tagliagambe A., Tonoli S., Valdagni R., Vavassori V., and Vinciguerra A.

Published
2016

10. Linee Guida AIRO-AIRB 2018: Neoplasie della Vescica

Author

Magrini, S., Santoni, R., Alongi, F., Arcangeli, S., Augurio, A, Belgioia, L., Bellavita, R., Bertone, F., Borghesi, S., Bruni, A., Buglione, M., Cardone, G., Corvò, R., D'Agostino, Gr, D'Angelillo, Rm, Fersino, S., Genovesi, D., Hurle, R., Ingrosso, G, Jereczek-Fossa, Ba, Lohr, F, Maccagnano, C, Mazzeo, E, Mortellaro, G., Munari, E., Muto, M., Nolà, F., Palumbo, I., Pasinetti, N., Silvestro, G., and Triggiani, L.

Subjects
Cancer Research, Urinary Bladder Neoplasms, Oncology, Humans, General Medicine
Published
2018

13. Guidelines on prostate carcinoma - AIRO, 2016

Author

Santoni R., Arcangeli S., Ingrosso G., Antognoni P., Mazzeo E., D'angelillo R. M., Buglione M., Borghesi S., Petitti T., Orecchia R., Russi E., Alitto A., Alongi F., Augurio A., Bellavita R., Bertoni F., Bonetta A., Bruni A., Cagna E., Cazzaniga L. F., Corvo R., D'agostino G., D'amico R., Detti B., De Renzi F., Fabrini M. G., Fersino S., Frascino V., Gambarini S., Genovesi D., Grazioli L., Guarneri A., Jereczek-Fossa B. A., Lancia A., Livi L., Magrini S. M., Mantini G., Mignogna M., Mirri M. A., Palumbo I., Pergolizzi S., Silvestro G., Rubino L., Tagliagambe A., Tonoli S., Valdagni R., Vavassori V., Vinciguerra A., Santoni, R, Arcangeli, S, Ingrosso, G, Antognoni, P, Mazzeo, E, D'Angelillo, R, Buglione, M, Borghesi, S, Petitti, T, Orecchia, R, Russi, E, Alitto, A, Alongi, F, Augurio, A, Bellavita, R, Bertoni, F, Bonetta, A, Bruni, A, Cagna, E, Cazzaniga, L, Corvo, R, D'Agostino, G, D'Amico, R, Detti, B, De Renzi, F, Fabrini, M, Fersino, S, Frascino, V, Gambarini, S, Genovesi, D, Grazioli, L, Guarneri, A, Jereczek-Fossa, B, Lancia, A, Livi, L, Magrini, S, Mantini, G, Mignogna, M, Mirri, M, Palumbo, I, Pergolizzi, S, Silvestro, G, Rubino, L, Tagliagambe, A, Tonoli, S, Valdagni, R, Vavassori, V, and Vinciguerra, A

Subjects
Leuprorelin, Gnrh Agonist, Gonadotropin-Releasing Hormone
Published
2016

23. Prostate cancer guidelines - AIRO, 2016

Author

Santoni, R., Arcangeli, S., Ingrosso, G., Antognoni, P., Mazzeo, E., D'Angelillo, Rm, Buglione, M, Borghesi, S, Petitti, T, Orecchia, R, Russi, E, Alitto, A, Alongi, F, Arcangeli, S, Augurio, A, Bellavita, R, Bertoni, F, Bonetta, A, Borghesi, Bruni, A, Cagna, E, Cazzaniga, Lf, Corvo, R, D'Agostino, G, D'Amico, R, Detti, B, De Renzi, F, Fabrini, Mg, Fersino, S, Frascino, V, Gambarini, S, Genovesi, D, Grazioli, L, Guarneri, A, Jereczek Fossa, Ba, Ingrosso, G, Lancia, A, Livi, L, Magrini, Sm, Mantini, G, Mazzeo, E, Mignogna, M, Mirri, Ma, Palumbo, I., Pergolizzi, Stefano, Silvestro, G., Rubino, L., Tagliagambe, A., Tonoli, S., Valdagni, R, Vavassori, V., and Vinciguerra, A.

Subjects
Medicine (all), Oncology, Cancer Research
Published
2016

24. Stereotactic body radiation therapy with hydrogel spacer: a salvage reirradiation strategy for prostate cancer recurrence

Author

Alba Fiorentino, Giaj Levra, N., Mazzola, R., Fersino, S., Ricchetti, F., Ballario, R., Ruggieri, R., and Alongi, F.

Subjects
Male, Salvage Therapy, Hydrogel, Neoplasm Recurrence, Polyethylene Glycol Dimethacrylate, Local, Adenocarcinoma, Humans, Hydrogel, Polyethylene Glycol Dimethacrylate, Neoplasm Recurrence, Local, Prostatic Neoplasms, Re-Irradiation
Published
2016

37. Weekly Cisplatin and Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results

Author

Fiorentino, A., primary, Giaj Levra, N., additional, Ricchetti, F., additional, Fersino, S., additional, Mazzola, R., additional, Tebano, U., additional, Sicignano, G., additional, Naccarato, S., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results